Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients.

 Sobi has been involved
in the development and
manufacturing of
recombinant protein drugs
since the technology was first
developed more than
30 years ago.

 We want to make a difference
to people with rare diseases.

By working closely
with patients and their relatives
we learn about their daily
challenges and needs.


Sobi has a diversified and growth-oriented commercial product portfolio within three business lines.
To products


Sobi attended the ISTH 2015 conference in Toronto, Canada. The ISTH video blog was broadcasted daily in order to share learnings. Both haemophilia specialists and patient representatives were interviewed.
Go to

Annual General Meeting 2016

The Annual General Meeting in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, will be held on Thursday, May 19, 2016 at 2.00 p.m. at Näringslivets Hus, Storgatan 19, Stockholm, Sweden
Read more

Presentation of Sobi's Interim Report July - September 2015

29 October, 2015 Sobi's Report for the third quarter was published - Revenues for the quarter totalled SEK 786 M (666), an increase of 18 per cent.

Share Price


Volume: 668,648
Ticker: SOBI
SSE Large